Physician profile
Igor Mamkin
NPI 1316260268
$1,964.08
in general payments reported to CMS, 2019-2025
20 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $122 · 2021: $336 · 2022: $268 · 2023: $335 · 2024: $329 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $983.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $288.63 | 2025 | Assure Wcd |
| Bardy Diagnostics, INC. | $273.27 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $203.92 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $192.63 | 2022-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $189.24 | 2019-2024 | |
| Abbott Laboratories | $162.46 | 2019-2023 | Mitraclip |
| Amarin Pharma, INC. | $112.68 | 2021-2023 | |
| Cvrx, INC. | $106.08 | 2022 | |
| Medtronic, INC. | $103.74 | 2023-2024 | Percept Pc Brainsense, Linq II |
| E.R. Squibb & Sons, L.L.C. | $54.14 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $49.41 | 2019-2024 | Xarelto |
| Irhythm Technologies, INC. | $36.82 | 2021-2024 | Zio Monitor, Zio Xt Patch |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.52 | 2019-2021 | |
| Terumo Medical Corporation | $31.04 | 2024 | Heartrail |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.26 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $25.17 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.09 | 2024 | Amvuttra |
| Amgen INC. | $17.14 | 2023 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $17.00 | 2019 | |
| Vanda Pharmaceuticals INC. | $14.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Mamkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.